ress release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of ANGPTL4 mAbs and its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    (1)Stefano Romeo et al., "Population-based resequencing of ANGPTL4

       uncovers variations that reduce triglycerides and increase HDL,"

       Nature Genetics, April 2007.


    Contact for Lexicon:

    Bobbie Faulkner

    Manager, Investor Relations

    281/863-3503

    

bfaulkner@lexpharma.com

CONTACT: Bobbie Faulkner, Manager, Investor Relations o
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
2. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
3. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
4. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
7. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
8. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
9. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
10. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
11. Point of Care Strep Tests Speed Treatment, Lower Costs